Civitas to price IPO of 5 million shares between $14.00 and $16.00

JPMorgan, BofA are bookrunners; Cowen, Oppenheimer are co-managers

By Devika Patel

Knoxville, Tenn., Sept. 15 – Civitas Therapeutics, Inc. will sell 5 million common shares in its initial public offering with a 30-day greenshoe of 750,000 additional shares, according to a Form S-1/A filed Monday with the Securities and Exchange Commission. The deal was announced Aug. 26.

The shares will be sold at a price expected to fall between $14.00 and $16.00 per share.

J.P. Morgan Securities LLC and BofA Merrill Lynch are the joint bookrunning managers. Cowen and Co. and Oppenheimer & Co. are the co-managers.

Proceeds will be used for development, manufacturing, working capital and other general corporate purposes.

The biopharmaceutical company is based in Chelsea, Mass. The company intends to list its common stock on the Nasdaq under the symbol “CVTS.”

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.